Results for "antiviral"
Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study
First published: 20 July 2009
Shionogi-GlaxoSmithKline Pharmaceuticals, LLC announced today results from a Phase 2a study evaluating antiviral activity of its investigational integrase inhibitor (INI), S/GSK1349572. The results...
Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects
First published: 13 September 2009
Shionogi-GlaxoSmithKline Pharmaceuticals, LLC announced today results from a Phase 1-2a study evaluating the pharmacokinetics (PK), safety and antiviral activity of its investigational integrase in...
First published: 29 September 2020
Zovirax, which features aciclovir as its active ingredient, is an antiviral treatment for cold sores.
FY 2019 results slides
First published: 05 February 2020
GSK IR booklet - May 2020
First published: 14 May 2020
GSK receives marketing authorisation from the European Commission for additional Revolade™
First published: 24 September 2013
GSK announced today that the European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with ch...
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®
First published: 28 January 2009
The UK is now one of the world’s leading countries in stockpiling antivirals for treating infected individuals in the event of an influenza pandemic
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
First published: 26 July 2013
GSK announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Revolade™ (eltrombopag).
First published: 19 August 2020
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
First published: 22 August 2019
ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration.